Literature DB >> 1582217

Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model.

D C Gritz1, P J McDonnell, T Y Lee, D Tang-Liu, B B Hubbard, A Gwon.   

Abstract

Ofloxacin, a new quinolone antibiotic with a broad spectrum of activity, is very effective against Pseudomonas aeruginosa in vitro. Its effectiveness was studied in a rabbit model of tobramycin-sensitive P. aeruginosa. Treatment groups received either vehicle, tobramycin 0.3%, or ofloxacin 0.3%. Twelve hours of treatment decreased the bacterial counts from a mean of 2.2 +/- 0.7 x 10(6) colony forming units (cfu) per cornea in the vehicle group to means of 513 +/- 670 and 435 +/- 524 cfu in the tobramycin and ofloxacin groups, respectively. This decrease in bacterial counts was statistically significant (p = 0.001 for tobramycin and ofloxacin each compared with control, p = 0.86 for tobramycin compared with ofloxacin). After seven days, all antibiotic-treated corneas were sterile and the epithelial defects healed at comparable rates. Aqueous humor drug levels were higher in infected eyes without an intact epithelium (p = 0.02); in eyes with intact epithelium, concentrations of ofloxacin were higher than were those of tobramycin (p = 0.002). In this animal model, ofloxacin proved to be an effective antibiotic with no evidence of toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582217     DOI: 10.1097/00003226-199203000-00008

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

Review 1.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

2.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.